Full text
PDFPage 973
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Mandelli F., Avvisati G., Amadori S., Boccadoro M., Gernone A., Lauta V. M., Marmont F., Petrucci M. T., Tribalto M., Vegna M. L. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med. 1990 May 17;322(20):1430–1434. doi: 10.1056/NEJM199005173222005. [DOI] [PubMed] [Google Scholar]
- Quesada J. R., Talpaz M., Rios A., Kurzrock R., Gutterman J. U. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986 Feb;4(2):234–243. doi: 10.1200/JCO.1986.4.2.234. [DOI] [PubMed] [Google Scholar]
- Roth M. S., Foon K. A. Alpha interferon in the treatment of hematologic malignancies. Am J Med. 1986 Nov;81(5):871–882. doi: 10.1016/0002-9343(86)90360-8. [DOI] [PubMed] [Google Scholar]
- Selby P., Kohn J., Raymond J., Judson I., McElwain T. Nephrotic syndrome during treatment with interferon. Br Med J (Clin Res Ed) 1985 Apr 20;290(6476):1180–1180. doi: 10.1136/bmj.290.6476.1180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Talpaz M., Kantarjian H. M., McCredie K., Trujillo J. M., Keating M. J., Gutterman J. U. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986 Apr 24;314(17):1065–1069. doi: 10.1056/NEJM198604243141701. [DOI] [PubMed] [Google Scholar]